NASDAQ:NBIX

Neurocrine Biosciences Stock Predictions

Healthcare > Drug Manufacturers - Specialty & Generic

Buy NBIX

*Your capital is at risk

$164.18

-1.88 (-1.13%)

At Close: Jun 25, 2026

Currently predicting for Mon, 29 Jun 2026

NBIX Live board

Community Bull/Bear

Target Next close

Join the NBIX prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

NBIX Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For NBIX

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

NBIX Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT NEUROCRINE BIOSCIENCES

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ON...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
JLL $298.94	1.61%	Jun 23
CBRE $133.21	1.03%	Jun 23
CAG $13.43	2.72%	Jun 23
TTEK $28.04	1.43%	Jun 23
NESR $25.07	7.62%	Jun 23

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by